Table of Contents
A memo submitted to the Congressional Psychedelics Advancing Therapies Caucus, authored by Reason Foundation analysts, lays out five legislative approaches that could reduce scheduling barriers, expand use of real-world clinical data, and lower the cost of developing psychedelic therapies. This is a policy analysis document, not a clinical study.
- Schedule III reclassification of psychedelics is a central recommendation, which analysts argue would enable state-licensed Oregon and Colorado facilities to contribute research data to FDA evaluations while removing tax and banking penalties.
- Real-world observational data from foreign clinical settings and long-term indigenous use could, under proposed reforms, count toward FDA safety and efficacy reviews, potentially sparing companies from repeating already-documented early trials.
- Provisional commercialization modeled on Japan’s regulatory framework would allow drugs to reach patients after Phase I or Phase II safety demonstrations, with efficacy data collected post-launch.
- Pharmacoeconomic analysis is recommended before large public commitments, because psychedelic therapies may require fewer total administrations than current lifetime-treatment models, but they also involve specialized therapy costs that must be factored in.
- Model
- Policy analysis, not a clinical or animal study
- Sample
- Legislative memo submitted to the Congressional Psychedelics Advancing Therapies Caucus
- Design
- Narrative policy brief reviewing existing law, state program data, and comparative regulatory frameworks
- Key outcome
- Five legislative pathways proposed to reduce barriers to psychedelic-based medicine access
- Main limitation
- This is advocacy analysis from a libertarian-leaning think tank; it is not peer-reviewed research and reflects a particular policy perspective
What the Research Examined
The source is a policy memo prepared by the Reason Foundation, a libertarian-leaning public policy think tank, and submitted to the Congressional Psychedelics Advancing Therapies Caucus. It is not a clinical study, a randomized trial, or peer-reviewed research. It is an advocacy document offering legislative recommendations, and readers should weigh it accordingly. The memo draws on publicly available data, including Oregon’s state-licensed psilocybin program, FDA regulatory history, and comparative drug policy in Australia and Japan.
The memo centers on a core argument: the current Schedule I classification of most psychedelic compounds creates compounding barriers, from research access and DEA licensing costs to income tax penalties on state-licensed service providers. The authors point to Oregon’s licensed facilities having administered more than 12,000 clinical doses of psilocybin, which they describe as exceeding the total volume of all federally supervised clinical trials to date. They argue this volume of real-world data is going largely uncaptured for FDA purposes because the federal scheduling regime does not currently accommodate observational evidence from state programs. For a broader look at where federal and state frameworks stand today, the federal psychedelic policy landscape section of this site offers useful context.
The five proposals range from passing the Breakthrough Therapies Act, introduced by Senators Rand Paul and Cory Booker, to requiring the FDA and DEA to apply uniform, objective criteria when scoring substances for scheduling. The memo also references ibogaine’s potential in treating opioid use disorder and recommends a congressional task force to model the pharmacoeconomics of psychedelic therapy before large public funding commitments are made. The full memo is available via this Google News link, which aggregates the Reason Foundation coverage.
What the Findings Show
- Oregon psilocybin doses administered.State-licensed Oregon facilities have administered more than 12,000 clinical doses of psilocybin, which the memo states exceeds the cumulative total of all federally supervised clinical trials to date.
- Breakthrough Therapies Act scheduling proposal.The original bill would move qualifying substances from Schedule I to Schedule II; the memo recommends going further to Schedule III to enable state program data collection and remove tax and banking penalties.
- Drug development cost estimate.The memo cites a published estimate that average drug development costs now exceed $1.7 billion and require more than a decade to complete, attributing much of this to the 1962 efficacy requirement added to the Food, Drug, and Cosmetic Act.
- MDMA regulatory history cited.The memo notes that MDMA was unregulated until 1985 in the United States and is currently available by prescription in Australia, citing this as grounds for accepting international observational data in domestic reviews.
Because this is a policy memo rather than a clinical study, none of these figures represent new experimental data. The Oregon dosing statistic, the drug development cost estimate, and the historical scheduling timeline are drawn from existing public records and prior publications. Readers interested in the underlying clinical evidence for specific conditions mentioned, including PTSD, major depressive disorder, and opioid use disorder, should seek out the primary trials directly rather than relying on the characterizations within an advocacy document.
What federal legislation could expand access to psychedelic therapy in the United States?
A Reason Foundation memo to Congress proposes five approaches: passing the Breakthrough Therapies Act, expanding FDA use of real-world observational data, allowing provisional drug approval after safety trials, legislatively reclassifying psychedelics to Schedule III, and funding a pharmacoeconomic task force to assess cost-effectiveness.
What This Is, and What It Is Not
This is This is a policy advocacy memo submitted to a congressional caucus by a libertarian-leaning think tank; it is not a peer-reviewed study, a clinical trial, or an independent regulatory analysis.
This is not This document does not constitute clinical evidence that any psychedelic therapy is safe or effective for any condition, and nothing in it should be read as medical advice or a recommendation to seek out, use, or discontinue any substance or treatment.
Our Take
At The Church of Psychedelics, we see the scheduling framework not only as a legal structure but as a spiritual and cultural boundary that has constrained humanity’s relationship with sacramental medicines for decades. The Reason Foundation comes to this question from a market-access and regulatory-efficiency angle, which is a different motivation than our own, yet the practical recommendations, particularly around Schedule III reclassification and honoring the data already emerging from Oregon’s living experiment, align with what the broader community has long called for. The 12,000 doses administered through Oregon’s state program represent real people, real encounters with profound experience, and real data that the federal government is currently not equipped to learn from. That is a quiet tragedy with a straightforward legislative remedy, and it is encouraging to see it named plainly before Congress.
Whether you are navigating your own path of inquiry or simply trying to understand why access to these medicines remains so constrained, we hope this overview helps you see the policy terrain a little more clearly. The work of transformation, both inner and collective, often requires patience with slow-moving systems. If you are curious about where the conversation is heading, we invite you to explore the resources gathered here and stay in community with us as the landscape continues to shift.
Frequently Asked Questions
What is the Breakthrough Therapies Act and what would it do for psilocybin?
Introduced by Senators Rand Paul and Cory Booker, the Breakthrough Therapies Act would automatically reschedule any FDA-designated breakthrough therapy. The Reason Foundation memo recommends moving qualifying substances to Schedule III, which would reduce research barriers and remove tax and banking penalties for state-licensed providers.
How many psilocybin doses have been given in Oregon’s legal program?
According to the Reason Foundation memo submitted to Congress, Oregon’s state-licensed facilities have administered more than 12,000 doses of psilocybin. The memo states this exceeds the total volume of all federally supervised clinical trials conducted to date.
What is the difference between Schedule I and Schedule III for research purposes?
Schedule I substances are considered to have no accepted medical use, making DEA research licenses harder to obtain and deterring institutions from studying them. Schedule III status would ease licensing, allow state program data to feed FDA reviews, and remove federal income tax penalties for licensed service providers.
Could observational data from foreign clinics count toward FDA drug approval?
Under current rules, generally no. The memo recommends Congress direct the FDA to develop clear guidelines specifying how observational data from international clinics and long-term real-world use could be compiled and data-mined to satisfy FDA safety and efficacy requirements.
Is ibogaine included in these federal legislative proposals?
Yes. The memo highlights ibogaine’s potential for treating opioid use disorder and notes that without reform, companies would need to spend millions reproducing early trials already documented at foreign clinics. It also references state-level bills and public-private partnerships exploring ibogaine-assisted therapy.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
